Literature DB >> 14991540

HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.

Judit Zubovits1, Elizabeth Buzney, Lawrence Yu, Lyn M Duncan.   

Abstract

The diagnosis of melanoma metastatic to lymph node remains a difficult problem given its histological diversity. We examined the staining patterns of S-100, NK1/C3, HMB-45, and MART-1 (DC10) in melanoma metastases to lymph nodes. Immunohistochemical stains were performed on tissue sections of 126 formalin-fixed lymph nodes from 126 patients with an established diagnosis of metastatic melanoma. A total of 98% of cases (123 of 126) stained positive for S-100, 93% (117 of 125) stained positive for NK1/C3, 82% (103 of 126) stained positive for MART-1, and 76% (95 of 125) stained positive for HMB-45. The distribution and intensity of staining varied among these markers. A diffuse staining pattern, defined as >50% of tumor cells stained, was observed in 83% of MART-1-positive cases but in only 56% of S-100-positive cases, 48% of NK1/C3-positive cases, and 34% of HMB-45-positive cases. A maximally intense signal was almost always observed for MART-1 (83% of positive cases) but was rarely observed for NK1/C3 (20%). S-100 and HMB-45 showed maximally intense staining in 50% and 54% of cases, respectively. S-100 and NK1/C3 stained both histiocytes and melanocytes, whereas MART-1 and HMB-45 stained only melanocytes. Seventy-eight cases (63%) stained positive for all 4 markers, 17 cases (14%) stained for all markers except HMB-45, 13 cases (10%) stained for all markers except MART-1, 6 cases (5%) stained only with S-100 and NK1/C3, 4 cases (3%) stained only with S-100 and HMB-45, and 2 cases stained for all markers except S-100. One case each stained for the following: only S-100, only S-100 and HMB-45, and all markers except NK1/C3. One case exhibited absence of staining for any of these markers. We demonstrate that lymph node metastases of melanoma are heterogeneous with regard to tumor marker expression. S-100 and NK1/C3 were the most sensitive stains for detecting metastatic melanoma; however, they both also stain other nontumor cells in lymph nodes. MART-1 did not stain histiocytes and exhibited a more frequently intense and diffuse staining pattern than NK1/C3. HMB-45 was less sensitive and demonstrated less diffuse staining than MART-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991540     DOI: 10.1016/j.humpath.2003.09.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

2.  Loss of S100 antigenicity in metastatic melanoma.

Authors:  Dara L Aisner; Ajay Maker; Steven A Rosenberg; David M Berman
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

3.  Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Authors:  Jad Saab; Maria Laureana Santos-Zabala; Massimo Loda; Edward C Stack; Travis J Hollmann
Journal:  Am J Dermatopathol       Date:  2018-04       Impact factor: 1.533

4.  Protein signatures for survival and recurrence in metastatic melanoma.

Authors:  William M Hardesty; Mark C Kelley; Deming Mi; Robert L Low; Richard M Caprioli
Journal:  J Proteomics       Date:  2011-04-23       Impact factor: 4.044

5.  Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival.

Authors:  Maria A Selim; James L Burchette; Edith V Bowers; Gustaaf G de Ridder; Lihong Mo; Salvatore V Pizzo; Mario Gonzalez-Gronow
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

6.  Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research.

Authors:  Lindsay G Wich; Heather K Hamilton; Richard L Shapiro; Anna Pavlick; Russell S Berman; David Polsky; Judith D Goldberg; Eva Hernando; Prashiela Manga; Michelle Krogsgaard; Hideko Kamino; Farbod Darvishian; Peng Lee; Seth J Orlow; Harry Ostrer; Nina Bhardwaj; Iman Osman
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

7.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

8.  Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Authors:  Hollis Viray; William R Bradley; Kurt A Schalper; David L Rimm; Bonnie E Gould Rothberg
Journal:  Arch Pathol Lab Med       Date:  2013-08       Impact factor: 5.534

Review 9.  Emerging Biomarkers in Cutaneous Melanoma.

Authors:  Anna Eisenstein; Estela Chen Gonzalez; Rekha Raghunathan; Xixi Xu; Muzhou Wu; Emily O McLean; Jean McGee; Byungwoo Ryu; Rhoda M Alani
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

10.  Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.

Authors:  Cecilia Lezcano; Melissa Pulitzer; Andrea P Moy; Travis J Hollmann; Achim A Jungbluth; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.